



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 24 August 2023

Ref. No.: TCPCL/SEC/2023-24/00050

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla, Complex Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Sub: Qualified institutions placement of equity shares of face value of ₹ 10 each (the “Equity Shares”) by Tatva Chintan Pharma Chem Limited (the “Company”) under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), and Sections 42 and 62 of the Companies Act, 2013 (including the rules made thereunder), as amended (the “Issue”).

Dear Sir/Madam,

We wish to inform you that pursuant to the approval accorded by the Board of Directors of the Company (the “**Board**”), at its meeting held on 11 July 2023 and the shareholders of the Company, pursuant to the special resolution passed by way of Postal Ballot on 13 August 2023, the Fund Raising Committee has, at its meeting held today i.e. 24 August 2023, *inter alia*, considered and approved the following resolutions:

- a. Authorizing the opening of the proposed issue of such number of Equity Shares to eligible qualified institutional buyers, aggregating to an amount up to ₹ 2,000 million, through a qualified institutions placement under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“**SEBI ICDR Regulations**”) and Section 42 of the Companies Act, 2013, read with Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014, each as amended (the “**Issue**”) today, i.e. 24 August 2023;
- b. Approving the floor price for the Issue, being ₹ 1,704.74 per Equity Share (“**Floor Price**”), based on the pricing formula as prescribed under the SEBI ICDR Regulations; and
- c. Approving and adopting the preliminary placement document dated 24 August 2023, together with the application form in connection with the Issue.

We further wish to inform you that the Fund Raising Committee has fixed the ‘relevant date’ for the purpose of the Issue, in terms of Regulation 171 of the SEBI ICDR Regulations, as 24 August 2023, and accordingly the floor price in respect of the Issue has been determined, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations, as ₹ 1,704.74 per Equity Share.

Pursuant to Regulation 176(1) of the SEBI ICDR Regulations and in accordance with the approval of the Shareholders accorded through a special resolution on 13 August 2023, the Company may at its discretion offer a discount of not more than 5% on the floor price so calculated for the Issue.

Registered Office and Factory : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** cs@tatvachintan.com **Website :** www.tatvachintan.com



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



The Issue price will be determined by the Company in consultation with the book running lead manager appointed for the Issue. Please note that the trading window will be closed with immediate effect until 48 hours after the Company obtains the listing and trading approval for the purpose of the Issue, in line with provisions of Securities and Exchange Board of India (Prohibition of Insider Trading Regulations, 2015, as amended).

The meeting of the Fund Raising Committee commenced at 07:00 p.m. and concluded at 11:00 p.m.

We request you to kindly take this on records, and the same be treated as compliance under Regulation 29(1) and 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

We request you to kindly take the information on your records.

Thanking you

**Your Faithfully,
For Tatva Chintan Pharma Chem Limited**

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444